Pharmaceutical executive John Klein serves as the chairman of Cambridge Therapeutics in New Jersey. In this capacity, he leverages more than two decades of experience in the pharmaceutical industry to set Cambridge Therapeutics’ strategic direction. To enhance his experience, John Klein stays abreast of state news that relate to the field.
A bill sponsored by Senator Troy Singleton was recently approved by the New Jersey Senate health committee that would bring more transparency to pharmaceuticals marketed and sold in the state, thus helping Garden State residents reduce their medication expenses.
Over the last several years, the rising costs of medication has become a major concern for many Americans. Reports from the New Jersey Health Care Quality Institute stated that drug prices rose 27 percent between 2012 and 2016, while overall healthcare spending only rose 18 percent in the state and 15 percent nationwide. Subsequently, Garden State hospitals have had to double budgets for pharmaceuticals between 2008 and 2017, as well as increase per-patient costs by an average of 132 percent.
Under the proposed bill, a public website would be created that listed specific drugs, along with information about their generic status, brand, and dosage. The per-unit wholesale cost of the medication would also be included on the website. Furthermore, pharmaceutical manufacturers and marketing agencies will be required to submit quarterly updates on pricing details to the State Board of Pharmacy. Companies that fail to do so will be fined between $200 and $20,000.
With nearly 30 years of experience in the healthcare and pharmaceutical industries, John Klein currently serves as the chairman of Cambridge Therapeutics in Teaneck, New Jersey. To inform the strategic decisions he makes as chairman of Cambridge Therapeutics, John Klein closely follows health policy developments in New Jersey.
The New Jersey State Assembly recently drafted a bipartisan bill to improve palliative care in the state. In addition to creating an 11-member advisory council on palliative care, the proposal would require hospitals, nursing homes, and other long-term care facilities to provide educational resources to patients and families about end-of-life care options.
Backed by about three dozen sponsors, the bill aims to increase public awareness about the full range of palliative care options and create a proactive system where care providers engage in educational outreach work. Providing different options for palliative care gives patients more control and may help ease some of the pain and anxiety associated with a terminal diagnosis, said Samantha DeAlmeida, a representative of the American Cancer Society, an organization that’s backing the New Jersey bill.
A distinguished pharmaceutical executive with almost 30 years of industry experience, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to guiding the business development of Cambridge Therapeutics, John Klein actively follows NJ news in the areas of health care policy.
New Jersey Governor Phil Murphy recently appointed Judith Persichilli to serve as the new head of the NJ Department of Health beginning in July 2019. A well-known hospital executive and registered nurse, Ms. Persichilli replaces Dr. Shereef Elnahal, who took a chief executive position with Newark’s University Hospital. The appointment awaits confirmation from the state’s Senate.
A resident of Pennington, Ms. Persichilli formerly served as the director of Trinity Health before spending much of 2018 at University Hospital, where she worked to study and reform the struggling facility. Nursing and hospital leaders, as well as the New Jersey Health Care Quality Institute that Ms. Persichilli helped establish, applauded her appointment. She is known for not only her experience as a clinician and administrative expertise in the health care sector, but also her strong leadership skills.
Executive John Klein serves as the chairman of Cambridge Therapeutics, a pharmaceutical company based in Teaneck, New Jersey. To inform the decisions he makes at Cambridge Therapeutics, John Klein follows healthcare-related news in New Jersey.
In May, an Assembly committee in the Garden State unanimously approved a new proposal that addresses loneliness and social isolation among seniors and other at-risk individuals in the Garden State, such as veterans and people with disabilities and mental illnesses. This decision comes after the creation of a task force by Democratic legislators to assess the frequency of social isolation among these groups.
A month prior, the National Institute on Aging published research results stating 28 percent of elderly adults in the United States live alone. While this doesn’t mean these individuals are lonely, it was noted that social isolation can increase the risk of heart disease, high blood pressure, and cognitive decline. Another study from the AARP Foundation also concluded that one in three people in the US over the age of 45 feel lonely.
The Assembly’s proposal to address this issue encourages the creation of new state programs for reducing the occurrence of loneliness. Their design would be based on common risk factors and loneliness levels among different groups as gauged by the task force on social isolation and loneliness. Further, the proposal calls for the panel to evaluate current state and local efforts to tackle the impact of social isolation.